Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity-Reference-Cited by-同舟云学术

Novel N-Linked Aminopiperidine Inhibitors of Bacterial Topoisomerase Type II: Broad-Spectrum Antibacterial Agents with Reduced hERG Activity

Published:2011-10-27 Issue:22 Volume:54 Page:7834-7847
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Reck Folkert¹,Alm Richard¹,Brassil Patrick¹,Newman Joseph¹,DeJonge Boudewijn¹,Eyermann Charles J.¹,Breault Gloria¹,Breen John¹,Comita-Prevoir Janelle¹,Cronin Mark¹,Davis Hajnalka¹,Ehmann David¹,Galullo Vincent¹,Geng Bolin¹,Grebe Tyler¹,Morningstar Marshall¹,Walker Phil²,Hayter Barry²,Fisher Stewart¹

Affiliation:

1. Infection Innovative Medicines Unit, AstraZeneca R&D Boston, 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States

2. AstraZeneca Research Support Laboratory, Block 25, Mereside, Alderley Park Macclesfield, Cheshire, SK10 4TG, United Kingdom

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm2008826

Reference39 articles.

1. Prevalence of Antimicrobial-Resistant Pathogens in Canadian Hospitals: Results of the Canadian Ward Surveillance Study (CANWARD 2008)

2. Type IIA topoisomerase inhibition by a new class of antibacterial agents